Deborah Siegal/LinkedIn
Mar 1, 2026, 10:31
Deborah Siegal Explores ARTESiA in The CLOT Conversation’s Latest Episode
Thrombosis Canada shared on LinkedIn:
”Major bleeding remains the leading complication of oral anticoagulation.
In our latest episode of CLOT Conversations, Dr. Deborah Siegal discusses the ARTESiA subanalysis examining major bleeding with apixaban versus aspirin in patients with device-detected subclinical atrial fibrillation.
Key insights:
- Apixaban reduced stroke/systemic embolism by 37%
- Major bleeding increased, largely driven by gastrointestinal events
- Intracranial and fatal bleeding rates were low and similar
- Most bleeding events were not clinical emergencies
- NSAID use emerged as a key modifiable risk factor
Understanding not just how often bleeding occurs, but how severe it is, is critical to individualized risk assessment and shared decision-making.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver